



Corrections and clarifications in the BNF

Date posted	Edition	Versions affected	Clarification or correction		Comment
			Location	Detail	
15 November 2011	62	Book and digital	Page 248, column 2, Page 250, column 2 and Page 251, column 1 Section 4.4	The indications and dosage information for modafinil in the printed version of BNF 62 (September 2011) is incorrect. The prescribing notes should read as follows:	The error will be corrected for the print edition of BNF 63 (March 2012) Digital versions of BNF 62 (September 2011) have been corrected.
				Modafinil is used for the treatment of excessive sleepiness associated with narcolepsy with or without cataplexy; dependence with long-term use cannot be excluded and it should therefore be used with caution.	
				The indication should read as follows:	
				Excessive sleepiness associated with narcolepsy with or without cataplexy	
				The dose should read as follows:	
Narcolepsy with or without cataplexy, ADULT over 18 years, initially 200mg daily, <i>either</i> in 2 divided doses morning and at noon <i>or</i> as a single dose in the morning, dose adjusted according to response to 200–400mg daily in 2 divided doses or as a single dose; ELDERLY initiate at 100mg daily; CHILD 5–18 years see <i>BNF for Children</i>					

8 November 2010	60	Book and digital	Page 560, column 2 Section 8.3.4.1	<p>The dose of fulvestrant by deep intramuscular injection for the treatment of oestrogen-receptor-positive metastatic or locally advanced breast cancer in post-menopausal women in whom disease progresses or relapses while on, or after, other anti-oestrogen therapy, in the printed version of BNF 60 (September 2010) is incorrect. The dose should read as follows:</p> <p>By deep intramuscular injection into buttock, 500 mg every 2 weeks for the first 3 doses, then 500 mg every month</p> <p>Note 500 mg dose should be administered as one 250-mg injection (slowly over 1–2 minutes) into each buttock</p>	<p>The error will be corrected for the print edition of BNF 61 (March 2011)</p> <p>Digital versions of BNF 60 (September 2010) have been corrected.</p>
11 October 2010	60	Book and digital	Page 254, column 1 Section 4.6	<p>The dose for palonosetron is incorrect: The statement “do not repeat dose within 7 days” is not correct and should be deleted. The entry should read as follows:</p> <p>By intravenous injection (over 30 seconds), 250 micrograms as a single dose 30 minutes before treatment; CHILD and ADOLESCENT under 18 years not recommended</p>	<p>The error will be corrected for the print edition for BNF 61 (March 2011). Digital versions of BNF 60 have been corrected</p>
13 September 2010	60	Book	Page 528, column 2 Section 8.1.4	<p>The preparation information for <i>Javlor</i>[®] concentrate for intravenous infusion is incorrect: the vial sizes for this product are 2mL and 10mL, not 2mL and 25mL. The entry should read as follows:</p> <p>Concentrate for intravenous infusion, vinflunine (as ditartrate) 25mg/mL, net price 2-mL vial = £212.50, 10-mL vial = £1062.50</p>	<p>The error will be corrected for the print edition of BNF 61 (March 2011)</p> <p>Digital versions of BNF 60 (September 2010) have been corrected.</p>

24 May 2010	59	Book & digital	Page 280, column 2 Section 4.8.1	<p>The dose of levetiracetam by intravenous infusion for adjunctive therapy of partial seizures, with or without secondary generalisation, in the printed version of BNF 59 (March 2010) is unlicensed in children under 4 years. The dose should read as below:</p>	<p>The error will be corrected for the print edition of BNF 60 (September 2010)</p> <p>Online versions of BNF 59 (March 2010) have been corrected. An update to correct this error will be available for other digital versions of BNF 59</p>
				<p>Adjunctive therapy of partial seizures with or without secondary generalisation, by mouth, ADULT and CHILD over 12 years, body-weight over 50 kg, initially 250 mg twice daily, adjusted in steps of 500 mg twice daily every 2–4 weeks; max. 1.5 g twice daily; CHILD over 6 months, body-weight under 50 kg, initially 10 mg/kg once daily, adjusted in steps not exceeding 10 mg/kg twice daily every 2 weeks; max. 30 mg/kg twice daily; CHILD 1–6 months, initially 7 mg/kg once daily, adjusted in steps not exceeding 7 mg/kg twice daily every 2 weeks; max. 21 mg/kg twice daily By intravenous infusion, ADULT and CHILD over 12 years, body-weight over 50 kg, initially 250 mg twice daily, adjusted in steps of 500 mg twice daily every 2–4 weeks; max. 1.5 g twice daily; CHILD over 4 years, body-weight under 50 kg, initially 10 mg/kg once daily, adjusted in steps not exceeding 10 mg/kg twice daily every 2 weeks; max. 30 mg/kg twice daily</p>	

21 April 2008	55	Book & digital	Page 487, column 1 Section 8.3.4.2	The indication and dose for bicalutamide 50mg tablets has been omitted in error. The indication should read:	The error will be corrected for the print edition of BNF 56 (September 2008) Online versions of BNF 55 (March 2008) have been corrected. An update to correct this error will be available for other digital versions of BNF 55
				Advanced prostate cancer in combination with gonadorelin analogue or surgical castration	
				The dose should read:	
				<ul style="list-style-type: none"> Advanced prostate cancer, in combination with gonadorelin analogue or surgical castration, 50mg once daily (started at the same time as surgical castration or at least 3 days before gonadorelin therapy, see also section 8.3.4.2, p. 486, BNF 55) 	
21 April 2008	55	Book	Page xiii, column 2 Late additions	The title of the new vaccine Ambirix [®] has been incorrectly spelt as Ambrix. The index shows the same incorrect proprietary title.	Online versions of BNF 55 have been corrected. An update to correct this error will be available for other digital versions of BNF 55. The correct preparation title will be included in section 14.4 for BNF 56.
2 November 2007	54	Book & digital	Page 165, column 1 Section 3.4.1	The strength of Xyzal [®] oral solution is incorrect. The preparation should read as follows: Oral solution ▼ , levocetirizine hydrochloride 2.5mg/5mL, net price 200 mL = £6.00. Counselling, driving	The error will be corrected for BNF 55 (March 2008)

17 October 2007	54	Book & digital	Page 469, column 2 Section 8.2.2	The dose of intravenous ciclosporin for the treatment of refractory ulcerative colitis in children is incorrect. The dose by intravenous infusion should read:	This error does not affect the adult dose The error will be corrected for the print edition of BNF 55 (March 2008) Online versions of BNF 54 (September 2007) have been corrected. An update to correct this error will be available for other digital versions of BNF 54
				CHILD 3–18 years initially 0.5–1 mg/kg twice daily; dose adjusted according to blood-ciclosporin concentration and response	
27 November 2006	52	Book & digital	Page 868, column 2	BNF 52 shows an incorrect email address for IVAX Pharmaceuticals.	Queries to IVAX should instead be made by post, telephone, or fax
8 November 2006	52	Book & digital	page 499, column 2 Section 9.5.2.1	The dose of phosphate in critically ill patients shown in the notes on phosphate supplements is incorrect in BNF52. The dose should read as follows:	The error will be corrected for BNF53 (March 2007)
				In critically ill patients, the dose of phosphate can be increased up to 500 micromol/kg (approx. 30 mmol in adults), infused over 6–12 hours, according to severity.	

31 October 2006	52	Book & digital	page 622, column 2 section 14.4	<p>The strength of one of the Tuberculin Purified Protein Derivative preparations is incorrect. The preparation entry should read:</p> <p>Injection, heat-treated products of growth and lysis of appropriate <i>Mycobacterium</i> spp. 20 units/mL (2 units/0.1-mL dose) (for routine use), 1.5-mL vial; 100 units/mL (10 units/0.1-mL dose), 1.5-mL vial</p>	The error will be corrected for BNF 53
31 March 2006	51	Book	page 704, column 1	<p>BNF 51 (Appendix 1) should contain the following interactions for mitotane:</p> <p>Mitotane</p> <ul style="list-style-type: none"> •Anticoagulants: mitotane possibly reduces anticoagulant effect of •coumarins <p>Antiepileptics: cytotoxics possibly reduce absorption of phenytoin</p> <ul style="list-style-type: none"> •Antipsychotics: avoid concomitant use of cytotoxics with •clozapine (increased risk of agranulocytosis) <p>Diuretics: manufacturer of mitotane advises avoid concomitant use of spironolactone (antagonism of effect)</p>	The error has been corrected for the digital versions of BNF 51. BNF 52 and <i>BNF for Children 2006</i> will show the interactions.
21 November 2005	50	Book & digital	page 439, column 1 section 8.1.5	<p>The pharmacology of bortezomib is incorrectly described in BNF 50. The notes on bortezomib should read:</p> <p>Bortezomib is a proteasome inhibitor,</p>	The error will be corrected in BNF 51 (March 2006).

November 2005	50	Book	Index, pages 832–866	A number of entries that should be indexed to General Guidance (pages 1–4) refer instead to an incorrect page number.	Only the book shows incorrect index entries; digital products are not affected.
19 January 2005	48	Book & digital	page 427, column 2	The side-heading above <i>DaunoXome</i> [®] is incorrect. <i>DaunoXome</i> [®] is for intravenous use, as described by the product entry and in the notes above. It is not for intrathecal use. The side-heading should read as follows: Lipid formulation	The error will be corrected in BNF 49 (March 2005). The BNF is grateful to pharmacists from James Paget Hospital who pointed out the mistake in the side-heading.
17 August 2004	47	Book & digital	page 313, column 1	BNF 47 shows an incorrect dose of clindamycin for the treatment of falciparum malaria in children. The dose should read as follows: clindamycin 20–40 mg/kg daily in 3 divided doses for 5 days [unlicensed indication]	Paediatric doses shown in the clindamycin monograph (section 5.1.6, p.276) are not affected. The error will be corrected for BNF 48 which is due to be published next month.